Easterly Investment Partners LLC Buys 5,028 Shares of Johnson & Johnson (NYSE:JNJ)

Easterly Investment Partners LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 6.3% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 85,144 shares of the company’s stock after acquiring an additional 5,028 shares during the period. Johnson & Johnson accounts for about 1.1% of Easterly Investment Partners LLC’s portfolio, making the stock its 23rd biggest position. Easterly Investment Partners LLC’s holdings in Johnson & Johnson were worth $12,445,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently modified their holdings of JNJ. Christopher J. Hasenberg Inc bought a new stake in Johnson & Johnson during the first quarter worth about $31,000. MFA Wealth Advisors LLC bought a new position in Johnson & Johnson during the 2nd quarter worth $43,000. Vermillion & White Wealth Management Group LLC bought a new stake in Johnson & Johnson in the fourth quarter valued at approximately $44,000. Disciplined Equity Management Inc. acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth $45,000. Finally, Grayhawk Investment Strategies Inc. boosted its position in shares of Johnson & Johnson by 528.6% during the 4th quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock valued at $48,000 after purchasing an additional 259 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on JNJ shares. TD Cowen dropped their target price on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research report on Thursday, July 18th. The Goldman Sachs Group cut their price objective on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research report on Friday, July 19th. Sanford C. Bernstein boosted their target price on Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Monday, August 5th. Finally, StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 16th. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $173.21.

Johnson & Johnson Price Performance

NYSE:JNJ traded up $1.78 during trading hours on Friday, hitting $164.13. 7,093,429 shares of the company’s stock traded hands, compared to its average volume of 7,299,449. The firm has a market cap of $395.01 billion, a P/E ratio of 10.23, a P/E/G ratio of 2.63 and a beta of 0.52. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The business’s fifty day simple moving average is $153.92 and its two-hundred day simple moving average is $153.20. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $167.78.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. During the same quarter in the previous year, the firm earned $2.80 earnings per share. Johnson & Johnson’s revenue was up 4.3% on a year-over-year basis. On average, research analysts anticipate that Johnson & Johnson will post 10.07 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.02%. The ex-dividend date is Tuesday, August 27th. Johnson & Johnson’s payout ratio is currently 30.92%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.